Back to Search Results
Image Place holder

Jessica Frakes, MD

★★★★★
★★★★★
4.9 (49 ratings)
Specialty: Radiation Oncology
Program: Radiation Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Adrenal Carcinoma, Anal Cancer, Appendiceal (Appendix) Cancer, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, GIST (Gastrointestinal Stromal Tumor), Liver Cancer, Pancreatic Cancer, Rectal Cancer

Dr. Jessica Frakes is an Associate Member in the Department of Radiation Oncology at Moffitt Cancer Center. She received her medical degree from the University of South Florida Morsani College of Medicine. Dr. Frakes completed her Radiation Oncology Residency at the University of South Florida / Moffitt Cancer Center. Her clinical expertise encompasses the use of radiation therapy to help patients diagnosed with gastrointestinal cancers, including esophageal, gastric, pancreatic, hepatobiliary, rectal and anal cancer. Dr. Frakes is dedicated to a personalized approach in designing advanced radiation techniques that include MRI guided adaptive radiation therapy, stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), as well as liver-directed therapies such as radiation embolization. Her research interests include improving outcomes and decreasing toxicity utilizing genomics and radiomics for the treatment of gastrointestinal cancers. She is dedicated to the advancement of multimodality treatments and the expansion of clinical trials. She is also the Program Director for the Radiation Oncology Residency Program at Moffitt Cancer Center.  


Education & Training

Residency:

  • University of South Florida Moffitt Cancer Center - Radiation Oncology

Medical School:

  • University of South Florida Morasani School of Medicine - MD
Participating Trials

CLINICAL TRIAL 20911
MRI Guided Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma to Enhance Complete Response
Condition: Gastrointestinal Tumor
Intervention: FOLFOX (); Xeloda (capecitabine); capecitabine ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kis B, Shridhar R, Mhaskar R, Gyano M, Frakes JM, El-Haddad G, Choi J, Kim RD, Hoffe SE. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma - A Prospective Feasibility Study. J Vasc Interv Radiol. 2023 May. Pubmedid: 37210030.
  • Bryant JM, Palm RF, Herrera R, Rubens M, Hoffe SE, Kim DW, Kaiser A, Ucar A, Fleming J, De Zarraga F, Hodul P, Aparo S, Asbun H, Malafa M, Jimenez R, Denbo J, Frakes JM, Chuong MD. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART). Cancer Control. 2023 Jan.30. Pubmedid: 36598464.
  • Pointer DT, McDonald JA, Naffouje SA, Mehta R, Fleming JB, Fontaine JP, Lauwers GY, Frakes JM, Hoffe SE, Pimiento JM. The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer. J Surg Oncol. 2022 Sep.126(3):465-478. Pubmedid: 35578777. Pmcid: PMC9339510.
  • Bibok A, Kis B, Frakes J, Hoffe S, Zhang J, Jain R, Parikh N. Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series. J Vasc Interv Radiol. 2022 Sep.33(9):1061-1065. Pubmedid: 36049841.
  • Kumar P, Mhaskar R, Kim R, Anaya D, Frakes J, Hoffe S, Choi J, Kis B. Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres. J Clin Exp Hepatol. 2022 Sep.12(5):1259-1263. Pubmedid: 36157145. Pmcid: PMC9499841.
  • Song EY, Chuang J, Frakes JM, Dilling T, Quinn JF, Rosenberg S, Johnstone P, Harrison L, Hoffe SE. Developing a Dedicated Leadership Curriculum for Radiation Oncology Residents. J Cancer Educ. 2022 Oct.37(5):1446-1453. Pubmedid: 33619686.
  • Bryant JM, Palm RF, Liveringhouse C, Boyer E, Hodul P, Malafa M, Denbo J, Kim D, Carballido E, Fleming JB, Hoffe S, Frakes J. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). Adv Radiat Oncol. 2022 Nov.7(6):101045. Pubmedid: 36420193. Pmcid: PMC9677195.
  • Tan E, Whiting J, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Walko C, Permuth JB, Sommerer K, Kim R, Anaya DA, Fleming JB, Sahin IH. BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. Oncologist. 2022 Mar.27(3):191-197. Pubmedid: 35274712. Pmcid: PMC8914499.
  • Sim AJ, Hoffe SE, Latifi K, Palm RF, Feygelman V, Leuthold S, Dookhoo M, Dennett M, Rosenberg SA, Frakes JM. A Practical Workflow for Magnetic Resonance-Guided Stereotactic Body Radiation Therapy to the Pancreas. Pract Radiat Oncol. 2022 Jul.13(1):e45-e53. Pubmedid: 35901947.
  • Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg. 2022 Feb.26(2):376-386. Pubmedid: 34506031.
  • Naffouje SA, Manguso N, Imanirad I, Sahin IH, Xie H, Hoffe S, Frakes J, Sanchez J, Dessureault S, Felder S. Neoadjuvant rectal score is prognostic for survival: A population-based propensity-matched analysis. J Surg Oncol. 2022 Dec.126(7):1219-1231. Pubmedid: 35916542.
  • Mills MN, Naz A, Sanchez J, Dessureault S, Imanirad I, Lauwers G, Moore M, Hoffe S, Frakes J, Felder S. Rectal tumor fragmentation as a response pattern following chemoradiation. J Gastrointest Oncol. 2022 Dec.13(6):2951-2962. Pubmedid: 36636056. Pmcid: PMC9830359.
  • Mehta R, Frakes J, Kim J, Nixon A, Liu Y, Howard L, Martinez Jimenez ME, Carballido E, Imanirad I, Sanchez J, Dessureault S, Xie H, Felder S, Sahin I, Hoffe S, Malafa M, Kim R. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. Oncologist. 2022 Aug.27(8):621-e617. Pubmedid: 35325225. Pmcid: PMC9355805.
  • Ehab J, Powers B, Kim R, Haider M, Utuama O, Chin A, Denbo J, Kis B, Frakes J, Jeong D, Lauwers G, Vadaparampil S, Fleming JB, Anaya DA. Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies. Ann Surg Oncol. 2022 Apr.29(4):2371-2380. Pubmedid: 34671878.
  • Ehab J, Powers B, Kim R, Haider M, Utuama O, Chin A, Denbo J, Kis B, Frakes J, Jeong D, Lauwers G, Vadaparampil S, Fleming JB, Anaya DA. ASO Visual Abstract: Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients with Liver Malignancies. Ann Surg Oncol. 2022 Apr.29(4):2381-2382. Pubmedid: 34716839.
  • Tan E, Whiting J, Knepper T, Xie H, Imanirad I, Carballido E, Felder S, Frakes J, Mo Q, Permuth JB, Somerer K, Kim R, Anaya DA, Fleming JB, Walko C, Sahin IH. Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. Am J Clin Oncol. 2022 Apr.45(4):137-141. Pubmedid: 35320814.
  • Wood AC, Zhang Y, Mo Q, Cen L, Fontaine J, Hoffe SE, Frakes J, Dineen SP, Pimiento JM, Walko CM, Mehta R. Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status. Oncologist. 2022 Apr.27(4):307-313. Pubmedid: 35380714. Pmcid: PMC8982441.
  • Barakat E, Bibok A, Rishi A, Ahmed A, Frakes JM, Hoffe SE, Armaghani AJ, Soyano AE, Costa RLB, El-Haddad G, Choi J, Kis B. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. Adv Radiat Oncol. 2021 Oct.7(1):100838. Pubmedid: 35071835. Pmcid: PMC8767250.
  • Bibok A, Mhaskar R, Jain R, Zhang J, Frakes J, Hoffe S, El-Haddad G, Parikh N, Ahmed A, Fishman MN, Choi J, Kis B. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. Cardiovasc Intervent Radiol. 2021 Nov.44(11):1755-1762. Pubmedid: 34312688.
  • Felder SI, Feuerlein S, Parsee A, Imanirad I, Sanchez J, Dessureault S, Kim R, Hoffe S, Frakes J, Costello J. Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. Abdom Radiol (NY). 2021 May.46(5):1783-1804. Pubmedid: 33111189.
  • Bigness A, Imanirad I, Sahin IH, Xie H, Frakes J, Hoffe S, Laskowitz D, Felder S. Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation. CA-Cancer J Clin. 2021 May.71(3):198-208. Pubmedid: 33592118.
  • McDonald J, Chuang CY, Hicks JK, Berry DK, Imanirad I, Rishi A, Frakes JM, Hoffe SE, Felder S. FANCD2 Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. Adv Radiat Oncol. 2021 May.6(5):100717. Pubmedid: 34258475. Pmcid: PMC8260782.
  • Yuan Z, Frazer M, Rishi A, Latifi K, Tomaszewski MR, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Zhang GG, Frakes JM. Pretreatment CT and PET radiomics predicting rectal cancer patients in response to neoadjuvant chemoradiotherapy. Rep Pract Oncol Radiother. 2021 Feb.26(1):29-34. Pubmedid: 33948299. Pmcid: PMC8086711.
  • Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiat Oncol. 2021 Dec.16(1):237. Pubmedid: 34911546. Pmcid: PMC8672552.
  • Saeed SM, Naffouje S, Mehta R, Hoffe SE, Fontaine JP, Lauwers GY, Shah P, Frakes J, Pimiento JM. Impact of histology classification on pathologic treatment response and overall survival in distal esophageal cancer patients: a propensity matched analysis. Dis Esophagus. 2021 Aug.34(8). Pubmedid: 32996568.
  • Sim AJ, Frakes JM, Hoffe SE, Wuthrick E, Dilling TJ, Rosenberg S. Novel MR-Guided Radiotherapy Elective Rotation for Radiation Oncology Trainees. Cureus. 2020 Sep.12(9):e10706. Pubmedid: 33133871. Pmcid: PMC7594659.
  • Yuan Z, Frazer M, Ahmed KA, Naqvi SMH, Schell MJ, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Torres-Roca JF, Hoffe SE, Frakes JM. Modeling precision genomic-based radiation dose response in rectal cancer. Future Oncol. 2020 Oct.16(30):2411-2420. Pubmedid: 32686956.
  • Frazer ML, Yang G, Felder S, McDonald J, Sanchez J, Dessureault S, Imanirad I, Carballido E, Kim RD, Hoffe SE, Frakes JM. Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation. Am J Clin Oncol. 2020 May.43(5):319-324. Pubmedid: 32028341.
  • Yuan Z, Frazer M, Zhang GG, Latifi K, Moros EG, Feygelman V, Felder S, Sanchez J, Dessureault S, Imanirad I, Kim RD, Harrison LB, Hoffe SE, Frakes JM. CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. J Med Imaging Radiat Oncol. 2020 Jun.64(3):444-449. Pubmedid: 32386109.
  • Song EY, Frakes JM, Extermann M, Klocksieben F, Mehta R, Saeed S, Hoffe SE, Pimiento JM. Clinical Factors and Outcomes of Octogenarians Receiving Curative Surgery for Esophageal Cancer. J Surg Res. 2020 Jul.251:100-106. Pubmedid: 32114211.
  • Kayaleh R, Krzyston H, Rishi A, Naziri J, Frakes J, Choi J, El-Haddad G, Parikh N, Sweeney J, Kis B. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study. J Vasc Interv Radiol. 2020 Jul.31(7):1060-1068. Pubmedid: 32534978.
  • Figura NB, Oliver DE, Mohammadi H, Martinez K, Grass GD, Hoffe SE, Johnstone PAS, Frakes JM. Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution Experience. Am J Clin Oncol. 2020 Feb.43(2):107-114. Pubmedid: 31764023.
  • Parsee AA, McDonald JA, Jiang K, Latifi K, Mehta R, Frakes JM, Pimiento JM, Hoffe SE. Radiation-induced hepatitis masquerading as metastatic disease: the importance of correlating diagnostic imaging with treatment planning. J Gastrointest Oncol. 2020 Feb.11(1):133-138. Pubmedid: 32175116. Pmcid: PMC7052759.
  • Song EY, Venkat P, Fradley M, Frakes JM, Klocksieben F, Fontaine J, Mehta R, Saeed S, Hoffe SE, Pimiento JM. Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgery. J Gastrointest Oncol. 2020 Feb.11(1):68-75. Pubmedid: 32175107. Pmcid: PMC7052762.
  • Rishi A, Zhang GG, Yuan Z, Sim AJ, Song EY, Moros EG, Tomaszewski MR, Latifi K, Pimiento JM, Fontaine JP, Mehta R, Harrison LB, Hoffe SE, Frakes JM. Pretreatment CT and 18 F-FDG PET-based radiomic model predicting pathological complete response and loco-regional control following neoadjuvant chemoradiation in oesophageal cancer. J Med Imaging Radiat Oncol. 2020 Dec.65(1):102-111. Pubmedid: 33258556.
  • Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC, Holmlund J, Herman J, Taniguchi CM. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). Int J Radiat Oncol Biol Phys. 2020 Dec.108(5):1399-1400. Pubmedid: 33427657.
  • Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2019 May.23(5):885-894. Pubmedid: 30374818.
  • Song E, Segarra D, Latifi K, Leuthold S, Belinc D, Pena L, Malafa M, Frakes JM, Hoffe SE. Recognition of Tumor Invasion of a Pancreatic Head Biliary Stent During Stereotactic Body Radiation Therapy. Pract Radiat Oncol. 2019 May.9(3):132-135. Pubmedid: 30708132.
  • Goffredo P, Robinson TJ, Frakes JM, Utria AF, Scott AT, Hassan I. Comparison of Anal Versus Rectal Staging in the Prognostication of Rectal Squamous Cell Carcinoma: A Population-Based Analysis. Dis Colon Rectum. 2019 Mar.62(3):302-308. Pubmedid: 30398999.
  • Machicado JD, Obuch JC, Goodman KA, Schefter TE, Frakes J, Hoffe S, Latifi K, Simon VC, Santangelo T, Ezekwe E, Edmundowicz SA, Brauer BC, Shah RJ, Hammad HT, Wagh MS, Attwell A, Han S, Klapman J, Wani S. Endoscopic Ultrasound Placement of Preloaded Fiducial Markers Shortens Procedure Time Compared to Back-Loaded Markers. Clin Gastroenterol H. 2019 Dec.17(13):2749-2758.e2. Pubmedid: 31042578.
  • Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 Aug.111(8):782-794. Pubmedid: 31086963. Pmcid: PMC6695305.
  • Saeed SM, Fontaine JP, Dam AN, Hoffe SE, Cameron M, Frakes J, Mehta R, Gurd E, Pimiento JM. Is Preoperative G-Tube Use Safe for Esophageal Cancer Patients?. J Am Coll Nutr. 2019 Aug.39(4):301-306. Pubmedid: 31397638.
  • Oliver DE, Mohammadi H, Figura N, Frakes JM, Yamoah K, Perez BA, Wuthrick EJ, Naghavi AO, Caudell JJ, Harrison LB, Torres-Roca JF, Ahmed KA. Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Semin Radiat Oncol. 2019 Apr.29(2):111-125. Pubmedid: 30827449.
  • Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Venkat PS, Ahmed KA, Demetriou S, Frakes JM, Kim Y, Kish JA, Russell JS, Otto KJ, Chung CH, Harrison LB, Trotti A, Caudell JJ. Patient choice for high-volume center radiation impacts head and neck cancer outcome. Cancer Med. 2018 Oct.7(10):4964-4979. Pubmedid: 30175512. Pmcid: PMC6198196.
  • Mohammadi H, Abuodeh Y, Jin W, Frakes J, Friedman M, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Hoffe S. Using the Albumin-Bilirubin (ALBI) grade as a prognostic marker for radioembolization of hepatocellular carcinoma. J Gastrointest Oncol. 2018 Oct.9(5):840-846. Pubmedid: 30505583. Pmcid: PMC6219966.
  • Goffredo P, Robinson TJ, Frakes JM, Beck AC, Kalakoti P, Hassan I. The impact of location on the prognosis of squamous cell carcinomas of the anorectal region. J Surg Res. 2018 Nov.231:173-178. Pubmedid: 30278926.
  • Orcutt ST, Abuodeh Y, Naghavi A, Frakes J, Hoffe S, Kis B, Anaya DA. Kinetic analysis of contralateral liver hypertrophy after radioembolization of primary and metastatic liver tumors. Surgery. 2018 May.163(5):1020-1027. Pubmedid: 29325784.
  • Goffredo P, Garancini M, Robinson TJ, Frakes J, Hoshi H, Hassan I. A National-Level Validation of the New American Joint Committee on Cancer 8th Edition Subclassification of Stage IIA and B Anal Squamous Cell Cancer. Ann Surg Oncol. 2018 Jun.25(6):1654-1660. Pubmedid: 29572706.
  • Frakes JM, Abuodeh YA, Naghavi AO, Echevarria MI, Shridhar R, Friedman M, Kim R, El-Haddad G, Kis B, Biebel B, Sweeney J, Choi J, Anaya D, Giuliano AR, Hoffe SE. Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. J Gastrointest Oncol. 2018 Jun.9(3):546-552. Pubmedid: 29998020. Pmcid: PMC6006034.
  • Jin WH, Hoffe SE, Shridhar R, Strom T, Venkat P, Springett GM, Hodul PJ, Pimiento JM, Meredith KL, Malafa MP, Frakes JM. Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail. J Gastrointest Oncol. 2018 Jun.9(3):487-494. Pubmedid: 29998014. Pmcid: PMC6006031.
  • Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol. 2018 Feb.117(2):150-159. Pubmedid: 28833197. Pmcid: PMC7771345.
  • Jin WH, Mellon EA, Frakes JM, Murimwa GZ, Hodul PJ, Pimiento JM, Malafa MP, Hoffe SE. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. J Gastrointest Oncol. 2018 Feb.9(1):24-34. Pubmedid: 29564168. Pmcid: PMC5848029.
  • Yang GQ, Mhaskar R, Rishi A, Naghavi AO, Frakes JM, Almhanna K, Fontaine J, Pimiento JM, Hoffe SE. Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy. Dis Esophagus. 2018 Dec.32(8). Pubmedid: 30597022.
  • Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, El-Haddad G, Biebel B, Parikh N, Arslan B, Hoffe SE, Frakes JM, Springett GM, Anaya DA, Malafa M, Chen DT, Chen Y, Kim RD, Shridhar R, Kis B. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2018 Aug.29(8):1101-1108. Pubmedid: 30042074. Pmcid: PMC7771272.
  • Strom T, Harrison LB, Giuliano AR, Schell MJ, Eschrich SA, Berglund A, Fulp W, Thapa R, Coppola D, Kim S, Frakes J, Foekens J, Mulé JJ, Torres-Roca JF. Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer. 2017 Oct.84:304-314. Pubmedid: 28863385. Pmcid: PMC5822441.
  • Saeed NA, Mellon EA, Meredith KL, Hoffe SE, Shridhar R, Frakes J, Fontaine JP, Pimiento JM, Kothari N, Almhanna K. Adjuvant chemotherapy and outcomes in esophageal carcinoma. J Gastrointest Oncol. 2017 Oct.8(5):816-824. Pubmedid: 29184685. Pmcid: PMC5674263.
  • Murimwa GZ, Venkat PS, Jin W, Leuthold S, Latifi K, Almhanna K, Pimiento JM, Fontaine JP, Hoffe SE, Frakes JM. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017 Oct.8(5):808-815. Pubmedid: 29184684. Pmcid: PMC5674260.
  • Frakes J, Mellon EA, Springett GM, Hodul P, Malafa MP, Fulp WJ, Zhao X, Hoffe SE, Shridhar R, Meredith KL. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. J Gastrointest Oncol. 2017 Oct.8(5):758-765. Pubmedid: 29184679. Pmcid: PMC5674250.
  • Mellon EA, Jin WH, Frakes JM, Centeno BA, Strom TJ, Springett GM, Malafa MP, Shridhar R, Hodul PJ, Hoffe SE. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta Oncol. 2017 Mar.56(3):391-397. Pubmedid: 27885876.
  • Oliver JA, Venkat P, Frakes JM, Klapman J, Harris C, Montilla-Soler J, Dhadham GC, Altazi BA, Zhang GG, Moros EG, Shridhar R, Hoffe SE, Latifi K. Fiducial markers coupled with 3D PET/CT offer more accurate radiation treatment delivery for locally advanced esophageal cancer. Endosc Int Open. 2017 Jun.5(6):E496-E504. Pubmedid: 28573183. Pmcid: PMC5451282.
  • Venkat PS, Shridhar R, Naghavi AO, Hoffe SE, Almhanna K, Pimiento JM, Fontaine JP, Abuodeh Y, Meredith KL, Frakes JM. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer. Dis Esophagus. 2017 Jul.30(7):1-9. Pubmedid: 30052899.
  • Zhang DG, Feygelman V, Moros EG, Latifi K, Hoffe S, Frakes J, Zhang GG. Superficial and peripheral dose in compensator-based FFF beam IMRT. J Appl Clin Med Phys. 2017 Jan.18(1):151-156. Pubmedid: 28291940. Pmcid: PMC5689887.
  • Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017 Feb.28(2):254-259. Pubmedid: 27955832. Pmcid: PMC7771309.
  • Luu C, Amaral M, Klapman J, Harris C, Almhanna K, Hoffe S, Frakes J, Pimiento JM, Fontaine JP. Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?. World J Gastroenterol. 2017 Dec.23(46):8193-8199. Pubmedid: 29290655. Pmcid: PMC5739925.
  • Bustamante L, Frakes J, Hoffe S, Kim R. Investigational drugs for treating anal cancer and future perspectives. Expert Opin Inv Drug. 2016 Sep.25(1):51-62. Pubmedid: 26560877.
  • Grass GD, Naghavi AO, Frakes JM, Perez BA, Dilling TJ. Treatment of Stage III Non-Small Cell Lung Cancer Patients With Concurrent Chemotherapy and Radiation (70 Gy): Equivalent or Superior to 60 or 74 Gy of RTOG 0617?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E428-E429. Pubmedid: 27674664.
  • Naghavi AO, Strom T, Abuodeh YA, Frakes JM, Ahmed KA, Harrison LB, Trotti A, Caudell JJ. Risk Factors for Recurrence in Human Papillomavirus-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E372-E373. Pubmedid: 27674513.
  • Jin W, Mellon EA, Hoffe SE, Frakes JM, Springett GM, Centeno BA, Kim R, Mahipal A, Pimiento JM, Malafa MP, Latifi K. Does Metabolic Tumor Volume Predict Tumor Regression Grade After Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E195. Pubmedid: 27674030.
  • Mohammadi H, Abuodeh YA, Jin W, Frakes JM, Friedman M, Biebel B, Choi J, El-Haddad GE, Kis B, Sweeney J, Kim R, Pimiento JM, Malafa MP, Anaya D, Hoffe SE. Using the ALBI Grade as a Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E194-E195.
  • Mellon EA, Hoffe SE, Frakes JM, Strom T, Springett GM, Shridhar R, Centeno BA, Malafa MP, Chuong MD, Hodul PJ. Predictors and Survival for Pathologic Tumor Response Grade in Borderline Resectable and Locally Advanced Pancreatic Cancer Treated With Induction Chemotherapy and Neoadjuvant Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):E165. Pubmedid: 27673949.
  • Glazer ES, Neill KG, Frakes JM, Coppola D, Hodul PJ, Hoffe SE, Pimiento JM, Springett GM, Malafa MP. Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas. Cancer Control. 2016 Oct.23(4):446-454. Pubmedid: 27842335.
  • Naghavi AO, Strom TJ, Ahmed KA, Echevarria MI, Abuodeh YA, Venkat PS, Frakes JM, Harrison LB, Trotti AM, Caudell JJ. Management of Oropharyngeal Cancer in the HPV Era. Cancer Control. 2016 Jul.23(3):197-207. Pubmedid: 27556659.
  • Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer. 2016 Feb.122(4):634-641. Pubmedid: 26565997.
  • Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016 Dec.22(47):10406-10414. Pubmedid: 28058021. Pmcid: PMC5175253.
  • Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, Hoffe SE, Naghavi AO, Abuodeh YA, Frakes JM, Eschrich SA, Torres-Roca JF. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Aug.95(5):1399-1404. Pubmedid: 27319288. Pmcid: PMC7771381.
  • Kothari N, Mellon E, Hoffe SE, Frakes J, Shridhar R, Pimiento J, Meredith K, Tran ND, Saeed N, Almhanna K. Outcomes in patients with brain metastasis from esophageal carcinoma. J Gastrointest Oncol. 2016 Aug.7(4):562-569. Pubmedid: 27563446. Pmcid: PMC4963374.
  • Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol. 2016 Aug.7(4):547-555. Pubmedid: 27563444. Pmcid: PMC4963371.
  • Frakes JM, Strom TJ, Naghavi AO, Trotti A, Rao NG, McCaffrey JC, Otto KJ, Padhya T, Caudell JJ. Outcomes of mucosal melanoma of the head and neck. J Med Imaging Radiat Oncol. 2016 Apr.60(2):268-273. Pubmedid: 26597431.
  • Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol. 2016 Apr.7(2):221-227. Pubmedid: 27034789. Pmcid: PMC4783738.
  • Strom T, Hoffe SE, Fulp W, Frakes J, Coppola D, Springett GM, Malafa MP, Harris CL, Eschrich SA, Torres-Roca JF, Shridhar R. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol. 2015 Oct.117(1):159-164. Pubmedid: 26235848. Pmcid: PMC7771365.
  • Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015 Oct.7(10):241-249. Pubmedid: 26483878. Pmcid: PMC4606178.
  • Frakes JM, Figura ND, Ahmed KA, Juan TH, Patel N, Latifi K, Sarangkasiri S, Strom TJ, Chinnaiyan P, Rao NG, Etame AB. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. J Neurosurg. 2015 Nov.123(5):1261-1267. Pubmedid: 26140482.
  • Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol. 2015 Nov.112(6):597-602. Pubmedid: 26394724.
  • Frakes JM, Strom T, Springett GM, Hoffe SE, Balducci L, Hodul P, Malafa MP, Shridhar R. Resected pancreatic cancer outcomes in the elderly. Geriatr Oncol. 2015 Mar.6(2):127-132. Pubmedid: 25555451.
  • Arora D, Frakes J, Scott J, Opp D, Johnson C, Song J, Harris E. Incidental radiation to uninvolved internal mammary lymph nodes in breast cancer. Breast Cancer Res Treat. 2015 Jun.151(2):365-372. Pubmedid: 25929764.
  • Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015 Jul.54(7):979-985. Pubmedid: 25734581.
  • Venkat PS, Hoffe SE, Frakes JM. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 24(3):1073274817729259. Pubmedid: 28975831. Pmcid: PMC5937228.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

49 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments